Hydrochlorothiazide Arrow

Hydrochlorothiazide Arrow is an oral tablet containing the thiazide diuretic hydrochlorothiazide. Marketed in the European Union, this prescription product is formulated to promote sodium and water excretion, helping to control blood pressure and reduce fluid accumulation. It belongs to the antihypertensive and diuretic therapeutic classes and is identified by ATC code C03AA03. The medication is supplied as a generic‑type product without a specified strength in this description.

Hydrochlorothiazide Arrow is prescribed for several conditions in which excess fluid or elevated blood pressure requires pharmacologic management.

- Hypertension (high blood pressure) management, either alone or in combination with other antihypertensives. - Edema associated with congestive heart failure, reducing peripheral fluid buildup. - Ascites and peripheral edema secondary to hepatic cirrhosis. - Fluid retention related to renal disease, such as nephrotic syndrome.

Like other thiazide diuretics, Hydrochlorothiazide Arrow may cause a range of adverse reactions; most are mild, dose‑related, and reversible, but clinicians monitor patients for less common events.

Common: - Increased urination and mild electrolyte shifts such as low potassium. - Dizziness or light‑headedness, especially after standing. - Elevated blood glucose or mild hyperuricemia. - Photosensitivity leading to sunburn‑like skin reactions.

Serious: - Severe dehydration or electrolyte imbalance (e.g., hyponatremia, hypokalemia). - Acute gout attacks triggered by rising uric acid levels. - Allergic reactions including rash, pruritus, or angioedema. - Pancreatitis or severe hepatic dysfunction reported rarely.

When prescribing Hydrochlorothiazide Arrow, healthcare providers consider several precautionary factors to minimize risk and ensure safe use.

- Assess renal function before initiation and periodically during therapy. - Monitor serum electrolytes, especially potassium, sodium, and magnesium. - Use caution in patients with a history of gout or hyperuricemia. - Evaluate blood glucose control in diabetic individuals, as thiazides may raise glucose levels. - Avoid in patients with known hypersensitivity to thiazide diuretics. - Consider pregnancy status; thiazides are generally avoided unless benefits outweigh risks.

Hydrochlorothiazide Arrow can alter the pharmacokinetics or pharmacodynamics of several medicines; recognizing these interactions helps prevent adverse outcomes.

Avoid: - Lithium, because thiazides reduce renal clearance and may cause toxicity. - Non‑steroidal anti‑inflammatory drugs (NSAIDs), which can blunt diuretic efficacy and impair renal function. - Cyclosporine or tacrolimus, increasing risk of nephrotoxicity.

Use with caution: - ACE inhibitors or ARBs, which together may enhance potassium loss and renal impairment. - Antidiabetic agents (insulin, sulfonylureas), as thiazides can raise blood glucose. - Anticoagulants (warfarin), where thiazides may increase INR.